

# **REMDESIVIR** solution for infusion for treating COVID-19

The Cheshire and Merseyside Area Prescribing Group recommends the prescribing of REMDESIVIR solution for infusion, by specialists only, for treating COVID-19 in accordance with NICE TA971.

## **RED**

NICE technology appraisal (TA) 971 (08 May 2024) recommends remdesivir as an option for treating COVID-19 in hospitals in:

- > adults, only if they have a high risk of serious illness (risk factors as defined in <u>section 5 of NICE's technology</u> appraisal guidance on <u>casirivimab plus imdevimab</u>, <u>nirmatrelvir plus ritonavir</u>, <u>sotrovimab and tocilizumab</u> for treating COVID-19)
- > babies, children and young people, only if they:
  - are aged 4 weeks to 17 years and weigh at least 3 kg, and:
    - o have pneumonia, and
    - o need supplemental oxygen, or
- > weigh at least 40 kg, and have a high risk of serious illness (risk factors as defined in <u>section 5 of NICE's</u> technology appraisal guidance on <u>casirivimab plus imdevimab</u>, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19).<sup>[1]</sup>

Remdesivir is only recommended if the company provides it according to the commercial arrangement. [1]

#### **Implementation**

- > Remdesivir must only be provided within hospital settings in accordance with the relevant Trust COVID Medicines Protocol.
- > Prescribing should be initiated and retained by a specialist clinician who is competent and experienced in the assessment and treatment of COVID-19.

### **Data collection requirement**

Submission of Blueteq forms for COVID-19 treatments is required by the prescribing organisation.

#### References

1. National Institute for Health and Care Excellence. Technology Appraisal TA971; Remdesivir and tixagevimab plus cilgavimab for treating COVID-19, 08 May 2024, Accessed 28 May 2024.

**Note**: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.

ICB approval date: 25 Jun 2024 Prescribing policy statement Review date: Jun 2026 (or earlier if there is significant new evidence relating to this recommendation) Version: 1.0